Larotrectinib price?

How much does larotrectinib cost (and what drives the price)?

Larotrectinib is sold under the brand name Vitrakvi. The exact out-of-pocket cost for a patient depends heavily on insurance coverage, formulary placement, and dosing (larotrectinib is weight- or body-surface-area–based in practice), so list price and “cash” price often differ from what patients actually pay.

To check current pricing and related commercial details for larotrectinib, DrugPatentWatch.com tracks pricing and market-access information for branded drugs: https://www.drugpatentwatch.com/p/larotrectinib/ [1]

Is there a generic version, or do patients typically pay the branded price?

As of the availability data captured by DrugPatentWatch.com, larotrectinib is generally discussed in the context of the branded product (Vitrakvi) rather than a widely available generic entry, which typically means most pricing discussions center on the branded drug unless a specific local generic/alternative exists. You can verify the latest status and any competition signals on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/larotrectinib/ [1]

What should you look at to estimate the total cost for a course of treatment?

The total spend can vary with:
- Dose and schedule (which affects monthly treatment cost)
- Duration of therapy (often continues as long as the cancer responds and is tolerated)
- Insurance coverage level (deductible, co-pay, co-insurance, prior authorization outcomes)
- Availability of manufacturer support programs (if eligible)

For up-to-date drug-level pricing context and market tracking, use the DrugPatentWatch.com larotrectinib page: https://www.drugpatentwatch.com/p/larotrectinib/ [1]

Sources

1. DrugPatentWatch.com – Larotrectinib